Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay N Cohn

Showing results (121-130 of 171) with videos related to

Pageof 18
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 29, 2004
Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trialJoel M Neutel, Michael A Weber, Stevo Julius, et al.
American Journal of Hypertension|January 31, 2004
Clinical experience with perindopril in African-American hypertensive patients: a large United States community trialJay N Cohn, Stevo Julius, Joel Neutel, et al.
American Heart Journal|January 6, 2005
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)Lawrence Baruch, Robert D Glazer, Nora Aknay, et al.
Journal of Cardiac Failure|November 30, 2010
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson, Scott Solomon, Laura Angelici, et al.
European Journal of Heart Failure|December 15, 2006
Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure TrialMariantonietta Cicoira, Aldo Pietro Maggioni, Roberto Latini, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 18, 2005
Expanding the definition and classification of hypertensionThomas D Giles, Bradford C Berk, Henry R Black, et al.
American Journal of Hypertension|December 6, 2008
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemiaJay N Cohn, Daniel J Wilson, Joel Neutel, et al.
Journal of Cardiac Failure|June 10, 2006
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson, Roberto Latini, Inder S Anand, et al.
European Journal of Heart Failure|June 22, 2013
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT studyAnastasia Lesogor, Jay N Cohn, Roberto Latini, et al.
European Heart Journal|February 27, 2004
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFTRoberto Latini, Serge Masson, Inder Anand, et al.
Pageof 18

Showing results (121-130 of 171) with videos related to

Sort By:
Pageof 18
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|September 29, 2004
Clinical experience with perindopril in elderly hypertensive patients: a subgroup analysis of a large community trialJoel M Neutel, Michael A Weber, Stevo Julius, et al.
American Journal of Hypertension|January 31, 2004
Clinical experience with perindopril in African-American hypertensive patients: a large United States community trialJay N Cohn, Stevo Julius, Joel Neutel, et al.
American Heart Journal|January 6, 2005
Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)Lawrence Baruch, Robert D Glazer, Nora Aknay, et al.
Journal of Cardiac Failure|November 30, 2010
Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson, Scott Solomon, Laura Angelici, et al.
European Journal of Heart Failure|December 15, 2006
Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure TrialMariantonietta Cicoira, Aldo Pietro Maggioni, Roberto Latini, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 18, 2005
Expanding the definition and classification of hypertensionThomas D Giles, Bradford C Berk, Henry R Black, et al.
American Journal of Hypertension|December 6, 2008
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemiaJay N Cohn, Daniel J Wilson, Joel Neutel, et al.
Journal of Cardiac Failure|June 10, 2006
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT)Serge Masson, Roberto Latini, Inder S Anand, et al.
European Journal of Heart Failure|June 22, 2013
Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT studyAnastasia Lesogor, Jay N Cohn, Roberto Latini, et al.
European Heart Journal|February 27, 2004
The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFTRoberto Latini, Serge Masson, Inder Anand, et al.
Pageof 18